Colitis, Ulcerative Clinical Trial
Official title:
Randomized-controlled Trial of Yoga for Ulcerative Colitis
Verified date | September 2015 |
Source | Universität Duisburg-Essen |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ethics Commission |
Study type | Interventional |
The aim of this randomized trial is to investigate the effects of a 12-week yoga intervention compared to self-care on quality of life, stress, psychological health, and physiological parameters in 77 patients with ulcerative colitis.
Status | Completed |
Enrollment | 77 |
Est. completion date | August 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Ulcerative colitis (clinical, endoscopic and histological diagnosis) - Disease duration at least 12 months - Clinical remission for at least 4 weeks and less than 12 months - CAI < 5 - IBDQ < 170 - Physical and mental ability to perform yoga - No regular practice of yoga or Pilates in the previous 12 months Exclusion Criteria: - Clinically active disease (CAI > 4 Rachmilewitz) - Complete resection of the colon - Acute, infectious or chronic active ulcerative colitis - Severe disease precluding yoga practice - Malignancy with a disease-free survival < 5 years except curatively treated basalioma of the skin - Alcohol or drug abuse - Dementia - Pregnancy |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen | Essen |
Lead Sponsor | Collaborator |
---|---|
Universität Duisburg-Essen | Deutsche Morbus Crohn / Colitis ulcerosa Vereinigung DCCV |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adherence | Intervention adherence (number of sessions attended and home practice diary) | 3 months | No |
Primary | Disease-specific quality of life | Inflammatory Bowel Disease Questionnaire (IBDQ) | 3 months | No |
Secondary | Disease-specific quality of life | Inflammatory Bowel Disease Questionnaire (IBDQ) | 6 months | No |
Secondary | Generic quality of life | 36-Item Short Form Health Survey (SF-36) | 3 months | No |
Secondary | Generic quality of life | 36-Item Short Form Health Survey (SF-36) | 6 months | No |
Secondary | Anxiety/depression | Hospital Anxiety and Depresion Scale (HADS) | 3 months | No |
Secondary | Anxiety/depression | Hospital Anxiety and Depresion Scale (HADS) | 6 months | No |
Secondary | Subjective stress | Perceived Stress Scale (PSS) | 3 months | No |
Secondary | Subjective stress | Perceived Stress Scale (PSS) | 6 months | No |
Secondary | Subjective stress | Perceived Stress Questionnaire (PSQ) | 3 months | No |
Secondary | Subjective stress | Perceived Stress Questionnaire (PSQ) | 6 months | No |
Secondary | Positive/negative affect | Positive and Negative Affect Schedule (PANAS) | 3 months | No |
Secondary | Positive/negative affect | Positive and Negative Affect Schedule (PANAS) | 6 months | No |
Secondary | Body awareness | Body Awareness Questionnaire (BAQ) | 3 months | No |
Secondary | Body awareness | Body Awareness Questionnaire (BAQ) | 6 months | No |
Secondary | Body responsiveness | Body Responsiveness Scale (BRS) | 3 months | No |
Secondary | Body responsiveness | Body Responsiveness Scale (BRS) | 6 months | No |
Secondary | Self-efficacy | General Self-Efficacy Scale | 3 months | No |
Secondary | Self-efficacy | General Self-Efficacy Scale | 6 months | No |
Secondary | C-reactive protein | C-reactive protein | 3 months | No |
Secondary | C-reactive protein | C-reactive protein | 6 months | No |
Secondary | Blood sedimentation rate | Blood sedimentation rate | 3 months | No |
Secondary | Blood sedimentation rate | Blood sedimentation rate | 6 months | No |
Secondary | Faecal calprotectin | Faecal calprotectin | 3 months | No |
Secondary | Faecal calprotectin | Faecal calprotectin | 6 months | No |
Secondary | Faecal lactoferrin | Faecal lactoferrin | 3 months | No |
Secondary | Faecal lactoferrin | Faecal lactoferrin | 6 months | No |
Secondary | Faecel PMN-elastase | Faecel PMN-elastase | 3 months | No |
Secondary | Faecel PMN-elastase | Faecel PMN-elastase | 6 months | No |
Secondary | Disease activity | Clinical Activity Index (CAI-Rachmilewitz) | 3 months | No |
Secondary | Disease activity | Clinical Activity Index (CAI-Rachmilewitz) | 6 months | No |
Secondary | Salivary cortisol level | Salivary cortisol level - cortisol awakening response | 3 months | No |
Secondary | Steroid sensitivity | Steroid sensitivity (IC50) | 3 months | No |
Secondary | Andrenergic sensitivity | Andrenergic sensitivity (IC50) | 3 months | No |
Secondary | Cholinergic sensitivity | Cholinergic sensitivity (IC50) | 3 months | No |
Secondary | Safety | Number of patients with adverse events/serious adverse events | 3 months | Yes |
Secondary | Safety | Number of patients with adverse events/serious adverse events | 6 months | Yes |
Secondary | Hemogram | Hemogram | 3 months | No |
Secondary | Hemogram | Hemogram | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Completed |
NCT03494764 -
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
|
Phase 2 | |
Recruiting |
NCT03937609 -
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
|
Phase 4 | |
Completed |
NCT00503243 -
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT02537210 -
Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis
|
N/A | |
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT00488631 -
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT00928681 -
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT05242484 -
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01036022 -
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT03841045 -
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
|
||
Active, not recruiting |
NCT05528510 -
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT02825914 -
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
|
N/A | |
Recruiting |
NCT06049017 -
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT04567628 -
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
|
||
Withdrawn |
NCT05999708 -
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT05611671 -
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
|
Phase 2 | |
Active, not recruiting |
NCT03596645 -
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03648541 -
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
|
Phase 2 |